Serotonin Transporter Inhibition Prevents and Reverses Monocrotaline-Induced Pulmonary Hypertension in Rats

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Circulation

• Publication date

  2005-05-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.104.524926PMID 15927991
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overexpression of the 5-Hydroxytryptamine Transporter Gene: Effect on Pulmonary Hemodynamics and Hypoxia-Induced Pulmonary Hypertension

  2004cited by this paper
• Genetic basis of pulmonary arterial hypertension: current understanding and future directions.

  2004cited by this paper
• Serotonin-Induced Smooth Muscle Hyperplasia in Various Forms of Human Pulmonary Hypertension

  2004cited by this paper
• Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats.

  2003cited by this paper
• Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension.

  2003cited by this paper
• Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension

  2002cited by this paper
• R-fluoxetine Increases Extracellular DA, NE, As Well As 5-HT in Rat Prefrontal Cortex and Hypothalamus: An in vivo Microdialysis and Receptor Binding Study

  2002cited by this paper
• Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension.

  2001cited by this paper
• Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension.

  2001cited by this paper
• Contribution of the 5-HT1B Receptor to Hypoxia-Induced Pulmonary Hypertension: Converging Evidence Using 5-HT1B-Receptor Knockout Mice and the 5-HT1B/1D-Receptor Antagonist GR127935

  2001cited by this paper
• Polarized distribution of interleukin-1 receptors and their role in regulation of serotonin transporter in placenta.

  2000cited by this paper
• Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene.

  2000cited by this paper
• Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin.

  1999cited by this paper
• Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients.

  1998cited by this paper
• Superoxide anion production by monocytes of corticosteroid-treated asthmatic patients.

  1998cited by this paper
• Pulmonary hypertension and inflammation.

  1998cited by this paper
• Behavioural sensitization of mesolimbic dopamine D2 receptors in chronic fluoxetine-treated rats.

  1997cited by this paper
• Pharmacokinetic-Pharmacodynamic Relationship of the Selective Serotonin Reuptake Inhibitors

  1996cited by this paper
• Regulation of the human serotonin transporter by interleukin-1 beta.

  1995cited by this paper
• Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension.

  1995cited by this paper
• Acute and chronic effects of fluoxetine and haloperidol on mouse brain serotonin and norepinephrine turnover.

  1995cited by this paper
• Occupancy of the serotonin transporter by fluoxetine, paroxetine, and sertraline: In vivo studies with [125i]rti‐55

  1994cited by this paper
• Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline.

  1994cited by this paper
• Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture.

  1991cited by this paper
• The Human Pulmonary Circulation: Its Form and Function in Health and Disease

  1987cited by this paper
• The Human Pulmonary Circulation: its Form and Function in Health and Disease

  1987cited by this paper
• Primary Pulmonary Hypertension: A Pathologic Study of the Lung Vessels in 156 Clinically Diagnosed Cases

  1970cited by this paper

• Altered Ventilation in Rats With Established Severe Monocrotaline‐Induced Pulmonary Hypertension: The Role of the Dorsal Hypothalamus

  2025cites this paper
• Advances in the discovery of drugs that treat pulmonary arterial hypertension

  2023cites this paper
• SSRIs: Applications in inflammatory lung disease and implications for COVID‐19

  2021cites this paper
• 5-HT2B Receptor in Cardiopulmonary Disease

  2021cites this paper
• Role of Medicinal Plants in Pulmonary Hypertension

  2021cites this paper
• Chronic Inhibition of Toll‐Like Receptor 9 Ameliorates Pulmonary Hypertension in Rats

  2021cites this paper
• The Expression of Proteins Related to Serotonin Pathway in Pulmonary Arteries of Dogs Affected With Pulmonary Hypertension Secondary to Degenerative Mitral Valve Disease

  2020cites this paper
• Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study

  2020cites this paper
• Involvement of proBDNF in Monocytes/Macrophages with Gastrointestinal Disorders in Depressive Mice

  2020cites this paper
• Pulmonary hypertension: Pathophysiology beyond the lung.

  2019cites this paper
• Autophagy in pulmonary hypertension: Emerging roles and therapeutic implications

  2019cites this paper
• New drugs, therapeutic strategies, and future direction for the treatment of Pulmonary Arterial Hypertension.

  2018cites this paper
• Drug-associated pulmonary arterial hypertension

  2018cites this paper
• Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension

  2018cites this paper
• Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again

  2018cites this paper
• Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension.

  2018cites this paper
• Anorexigen-Associated Pulmonary Arterial Hypertension and the Serotonin Hypothesis: A Story Worth Telling

  2018cites this paper
• Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists.

  2018cites this paper
• New targets for pulmonary arterial hypertension: going beyond the currently targeted three pathways

  2017cites this paper
• Challenges in the development of chronic pulmonary hypertension models in large animals

  2017cites this paper
• Vesicle miR-195 derived from Endothelial Cells Inhibits Expression of Serotonin Transporter in Vessel Smooth Muscle Cells

  2017cites this paper
• Upregulation of SERT and ADORA1 in broilers with acute right ventricular failure.

  2017cites this paper
• Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension

  2017cites this paper
• Pathology and Pathobiology of Pulmonary Hypertension

  2017cites this paper
• Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension

  2017cites this paper
• [Towards new targets for the treatment of pulmonary arterial hypertension : Importance of cell-cell communications].

  2016cites this paper
• Update in treatment options in pulmonary hypertension.

  2016cites this paper
• Translationally Controlled Tumour Protein as a Novel Therapeutic Target in Pulmonary Arterial Hypertension

  2016cites this paper
• Targeting the Cause, affecting the Course: Characterization and Optimization of Experimental Models for Pulmonary Arterial Hypertension

  2016cites this paper
• Medical therapies for pulmonary arterial hypertension

  2016cites this paper
• The Serotonin Transporter Promotes a Pathological Estrogen Metabolic Pathway in Pulmonary Hypertension via Cytochrome P450 1B1

  2016influential citation
• Inflammation et maladies pulmonaires : implications pour le traitement de l’hypertension artérielle pulmonaire et pour la vaccination antigrippale

  2016cites this paper
• Nouvelles approches diagnostiques et thérapeutiques dans l'hypertension pulmonaire : apport de la tomodensitométrie et identification du facteur de croissance des nerfs NGF comme nouvelle cible thérapeutique

  2016cites this paper
• Growth Factors and Aging in Pulmonary Arterial Hypertension

  2016cites this paper
• Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways

  2016cites this paper
• Activation of Calpain-2 by Mediators in Pulmonary Vascular Remodeling of Pulmonary Arterial Hypertension.

  2016cites this paper
• Physiopathology of Pulmonary Hypertension: from Bio-Molecular Mechanism to Target Treatment

  2016cites this paper
• Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future.

  2016cites this paper
• Treatment of Idiopathic Pulmonary Arterial Hypertension: Current and Clinical Trial Modalities

  2016cites this paper
• Insights Into the Pathobiology of Pulmonary Hypertension

  2015cites this paper
• Anti–Endothelin Receptor Type A Autoantibodies in Systemic Lupus Erythematosus–Associated Pulmonary Arterial Hypertension

  2015cites this paper
• Leptin signalling system as a target for pulmonary arterial hypertension therapy

  2015cites this paper
• Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex.

  2015cites this paper
• Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach.

  2015cites this paper
• The Serotonin Transporter Promotes a Pathological Estrogen Metabolic Pathway in Pulmonary Hypertension via Cytochrome P 450 1 B 1 Running title : Serotonin transporter , estrogen , CYP 1 B 1 and pulmonary hypertension

  2015cites this paper
• Mammalian target of rapamycin overexpression antagonizes chronic hypoxia-triggered pulmonary arterial hypertension via the autophagic pathway.

  2015cites this paper
• Increased pulmonary vascular expression of receptor for advanced glycation end products (RAGE) in experimental congenital diaphragmatic hernia.

  2015cites this paper
• Pathogenic Mechanisms of Pulmonary Hypertension

  2015cites this paper
• Serotonin transporter is not required for the development of severe pulmonary hypertension in the Sugen hypoxia rat model.

  2015cites this paper
• Novel Targets of Drug Treatment for Pulmonary Hypertension

  2015cites this paper
• Regulation of Cell Cycle Regulators by SIRT1 Contributes to Resveratrol-Mediated Prevention of Pulmonary Arterial Hypertension

  2015cites this paper
• Potassium channels in pulmonary arterial hypertension

  2015cites this paper
• New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication.

  2015cites this paper
• The Xanthine Derivative KMUP-1 Attenuates Serotonin-Induced Vasoconstriction and K+-Channel Inhibitory Activity via the PKC Pathway in Pulmonary Arteries

  2015influential citation
• Novel investigational therapies for treating pulmonary arterial hypertension

  2015cites this paper
• Increased pulmonary vascular expression of Krüppel-like factor 5 and activated survivin in experimental congenital diaphragmatic hernia

  2014cites this paper
• Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension

  2014cites this paper
• Increased Pericyte Coverage Mediated by Endothelial-Derived Fibroblast Growth Factor-2 and Interleukin-6 Is a Source of Smooth Muscle–Like Cells in Pulmonary Hypertension

  2014cites this paper
• Upregulation of serotonin-receptor-2a and serotonin transporter expression in the pulmonary vasculature of nitrofen-induced congenital diaphragmatic hernia.

  2014cites this paper
• Interdisciplinary Concepts in Cardiovascular Health

  2014cites this paper
• Decreased apelin and apelin-receptor expression in the pulmonary vasculature of nitrofen-induced congenital diaphragmatic hernia

  2014cites this paper
• Rôle de la sérotonine et de la connexine 43 dans la paroi artérielle pulmonaire : implications dans l'hypertension pulmonaire

  2014cites this paper
• Identification of inhibitors of tryptophan hydroxylase 1

  2014cites this paper
• 4-Chloro-DL-phenylalanine protects against monocrotaline‑induced pulmonary vascular remodeling and lung inflammation.

  2014cites this paper
• The influence of gender and sex hormones in the development of translational and experimental pulmonary arterial hypertension

  2014cites this paper
• p21-Dependent Protective Effects of a Carbon Monoxide–Releasing Molecule-3 in Pulmonary Hypertension

  2014cites this paper
• Increased Pericyte Coverage Mediated by Endothelial Derived FGF-2 and IL-6 is a Source of Smooth Muscle-Like Cells in Pulmonary Hypertension Running title: Ricard et al.; Pericytes in pulmonary arterial hypertension

  2014cites this paper
• Proteomic remodeling of proteasome in right heart failure.

  2014cites this paper
• Emerging molecular targets for anti-proliferative strategies in pulmonary arterial hypertension.

  2013cites this paper
• Association between serotonin transporter (SERT) gene polymorphism and idiopathic pulmonary arterial hypertension: a meta-analysis and review of the literature.

  2013cites this paper
• Inhaled PLGA particles of prostaglandin E₁ ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency.

  2013cites this paper
• Targeting the serotonin pathway for the treatment of pulmonary arterial hypertension.

  2013cites this paper
• Echocardiographic assessment of the impact of exercise training at different time points of the development of experimental pulmonary arterail hypertension

  2013cites this paper
• Serotonin contributes to high pulmonary vascular tone in a sheep model of persistent pulmonary hypertension of the newborn.

  2013cites this paper
• Assessment of the serotonin pathway as a therapeutic target for pulmonary hypertension.

  2013influential citation
• Pediatric pulmonary hypertension.

  2013cites this paper
• Iptakalim Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats

  2013cites this paper
• 5-Hydroxytryptamine levels in the pulmonary arterioles of broilers with induced pulmonary hypertension and its relationship to pulmonary vascular remodelling

  2013cites this paper
• Pathology and Pathobiology of Pulmonary Hypertension

  2013cites this paper
• Serotonin transporter and serotonin receptors.

  2013cites this paper
• Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression.

  2013cites this paper
• Fluoxetine Attenuates Chronic Methamphetamine‐induced Pulmonary Arterial Remodelling: Possible Involvement of Serotonin Transporter and Serotonin 1B Receptor

  2013cites this paper
• Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension

  2013cites this paper
• Survivin and Smac/DIABLO: role of apoptosis in experimental PAH

  2013cites this paper
• Today’s and tomorrow’s imaging and circulating biomarkers for pulmonary arterial hypertension

  2012cites this paper
• Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats.

  2012cites this paper
• Combined effects of the ATP-sensitive potassium channel opener pinacidil and simvastatin on pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension.

  2012cites this paper
• Platelet-Mediated Mesenchymal Stem Cells Homing to the Lung Reduces Monocrotaline-Induced Rat Pulmonary Hypertension

  2012cites this paper
• [Pulmonary hypertension: from molecular pathophysiology to haemodynamic abnormalities].

  2012cites this paper
• heart and lung injury by neonatal hyperoxia in rats Phosphodiesterase 4 inhibition attenuates persistent

  2012cites this paper
• Fluoxetine may worsen hyperoxia-induced lung damage in neonatal rats.

  2012cites this paper
• Hypertension pulmonaire : de la physiopathologie moléculaire aux anomalies hémodynamiques

  2012cites this paper
• Immune and inflammatory mechanisms in pulmonary arterial hypertension.

  2012cites this paper
• Fluoxetine inhibits monocrotaline-induced pulmonary arterial remodeling involved in inhibition of RhoA-Rho kinase and Akt signalling pathways in rats.

  2012cites this paper
• Fluoxetine Protects against Big Endothelin-1 Induced Anti-Apoptosis by Rescuing Kv1.5 Channels in Human Pulmonary Arterial Smooth Muscle Cells

  2012cites this paper
• Effects of dapoxetine on cloned Kv1.5 channels expressed in CHO cells

  2012cites this paper
• Gene therapy by targeted adenovirus-mediated knockdown of pulmonary endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension.

  2012cites this paper
• A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.

  2012cites this paper
• Third trimester fetal pulmonary artery Doppler blood flow velocity characteristics following prenatal selective serotonin reuptake inhibitor (SSRI) exposure.

  2012cites this paper
• Terameprocol effect in the proliferation and apoptosis of SMCs in PAH

  2012cites this paper